Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Wood

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Reassuring Data for Cardiovascular Health After Switching a Boosted Protease Inhibitor to DolutegravirBrian R Wood
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2019
Do Integrase Inhibitors Cause Weight Gain?Brian R Wood
AIDS (London, England)|October 25, 2023
Metabolic dysfunction associated steatotic liver disease in persons with HIV: understanding the serious implications and renaming of 'fatty liver disease'Brian R Wood
AIDS (London, England)|November 16, 2020
Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policyBrian R Wood
Infectious Disease Clinics of North America|July 1, 2019
Switching Antiretroviral Therapy in the Setting of Virologic Suppression: A Why and How-To GuideBrian R Wood
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 27, 2015
Nonoccupational Postexposure Prophylaxis (nPEP) Visits: Opportunities Beyond HIV PEPBrian R Wood
AIDS (London, England)|January 31, 2020
Prevention of HIV for persons with low-frequency, high-risk exposures: PrEP (preexposure prophylaxis), PEP (postexposure prophylaxis), or 'PIP' (postexposure prophylaxis in-pocket)Brian R Wood
AIDS (London, England)|December 29, 2025
Doravirine/islatravir for heavily treatment-experienced adults with HIV: promise interruptedBrian R Wood
AIDS (London, England)|June 29, 2021
Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settingsTafireyi Marukutira, Brian R Wood
AIDS (London, England)|February 1, 2024
Early adopters of long-acting injectable cabotegravir/rilpivirine: what lessons can we learn?Brian R Wood, Nagalingeswaran Kumarasamy
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Reassuring Data for Cardiovascular Health After Switching a Boosted Protease Inhibitor to DolutegravirBrian R Wood
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2019
Do Integrase Inhibitors Cause Weight Gain?Brian R Wood
AIDS (London, England)|October 25, 2023
Metabolic dysfunction associated steatotic liver disease in persons with HIV: understanding the serious implications and renaming of 'fatty liver disease'Brian R Wood
AIDS (London, England)|November 16, 2020
Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policyBrian R Wood
Infectious Disease Clinics of North America|July 1, 2019
Switching Antiretroviral Therapy in the Setting of Virologic Suppression: A Why and How-To GuideBrian R Wood
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 27, 2015
Nonoccupational Postexposure Prophylaxis (nPEP) Visits: Opportunities Beyond HIV PEPBrian R Wood
AIDS (London, England)|January 31, 2020
Prevention of HIV for persons with low-frequency, high-risk exposures: PrEP (preexposure prophylaxis), PEP (postexposure prophylaxis), or 'PIP' (postexposure prophylaxis in-pocket)Brian R Wood
AIDS (London, England)|December 29, 2025
Doravirine/islatravir for heavily treatment-experienced adults with HIV: promise interruptedBrian R Wood
AIDS (London, England)|June 29, 2021
Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settingsTafireyi Marukutira, Brian R Wood
AIDS (London, England)|February 1, 2024
Early adopters of long-acting injectable cabotegravir/rilpivirine: what lessons can we learn?Brian R Wood, Nagalingeswaran Kumarasamy
Pageof 6